

## Innoviva to Participate in Baird Global Healthcare Conference on September 7

BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer will participate in the 2017 Baird Global Healthcare Conference at The InterContinental New York Barclay Hotel on Thursday, September 7, from 12:50 pm - 1:20 pm ET.

The presentation will be available to interested parties live and for 90 days following the presentation using the following link: <a href="http://wsw.com/webcast/baird49/inva">http://wsw.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://wsw.com/webcast/baird49/inva">www.inva.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://www.com/webcast/baird49/inva">www.com/webcast/baird49/inva</a> or via the investor relations section of the Innoviva website at <a href="http://www.com/webcast/baird49/inva">www.com/webcast/baird49/inva</a> or via the investor of the investor of

## **About Innoviva**

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for Chronic Obstructive Pulmonary Disease (COPD). For more information, please visit Innoviva's website at <a href="https://www.inva.com">www.inva.com</a>.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006020/en/

Innoviva, Inc.
Eric d'Esparbes
Senior Vice President and Chief Financial Officer
650-238-9640
investor.relations@inva.com

Source: Innoviva, Inc.

News Provided by Acquire Media